OKYO Pharma Limited Sponsored ADR (OKYO) Price & Analysis

Compare

88 Followers

OKYO Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.90 - $3.35

Previous CloseN/A

Volume700.83K

Average Volume (3M)200.94K

Market Cap

$89.89M

Enterprise Value$44.19M

Total Cash (Recent Filing)$987.20K

Total Debt (Recent Filing)$1.81K

Price to Earnings (P/E)―

Beta0.36

Next Earnings

Aug 05, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.09

Shares Outstanding37,610,676

10 Day Avg. Volume181,468

30 Day Avg. Volume200,942

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.49

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$10.00

Price Target Upside338.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

Bulls Say, Bears Say

Bulls Say

Analyst ConfidenceAnalysts reiterate a Buy rating for OKYO Pharma, reflecting confidence in the company's prospects.

Clinical Trial SuccessPositive proof-of-concept data from the Phase 2 trial of urcosimod for the treatment of neuropathic corneal pain was announced by OKYO Pharma.

Regulatory AdvancementThe FDA granted Fast Track designation to urcosimod for the treatment of neuropathic corneal pain, allowing for more frequent meetings and quicker communication with the FDA.

Bears Say

Development UncertaintyEarly closure of the Phase 2 trial was announced to accelerate the clinical development of urcosimod for treating neuropathic corneal pain.

Patient DemandA number of patients from the trial have requested continued compassionate use of urcosimod, subject to necessary FDA consents, and a considerable number of potential patients have expressed an interest in participating in a future registrational trial.

OKYO Pharma Limited Sponsored ADR News

Okyo Pharma initiated with a Buy at Lucid Capital

Lucid Capital analyst Elemer Piros initiated coverage of Okyo Pharma (OKYO) with a Buy rating and $13 price...

30d ago

OKYO

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) just unveiled an update. On July 17, 2025, OKYO Pharma...

1M ago

OKYO

Okyo Pharma receives $1.9M in non-dilutive funding

OKYO Pharma (OKYO) announced it has received $1.9 million in non-dilutive funding to support its ongoing research and...

1M ago

OKYO

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on OKYO Pharma Limited...

1M ago

OKYO

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain

An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On July 16, 2025,...

1M ago

OKYO

Okyo Pharma reports Phase 2 clinical trial results for urcosimod

OKYO Pharma (OKYO) announced top-line data from the recently closed 18-patient Phase 2 trial of urcosimod to treat...

1M ago

OKYO

OKYO Pharma CEO to Present Urcosimod Development at Bio International Convention

An update from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On June 11, 2025,...

3M ago

OKYO

OKYO Pharma CEO to Present at Boston Drug Discovery Summit

OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) has shared an update. On May 19, 2025, OKYO Pharma...

3M ago

OKYO

OKYO Pharma’s Urcosimod Receives FDA Fast Track Designation for Neuropathic Corneal Pain

An announcement from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ) is now available. On May 1, 2025,...

4M ago

OKYO

Okyo Pharma announces FDA granted FTD to urcosimod

OKYO Pharma (OKYO) announces that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation, FTD,...

4M ago

OKYO

Promising Developments in OKYO Pharma’s Urcosimod Program Drive Buy Rating and $7 Price Target

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on OKYO Pharma Limited Sponsored ADR (OKYO –...

4M ago

OKYO

OKYO Pharma Accelerates Urcosimod Development for Neuropathic Corneal Pain

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On April 30, 2025,...

4M ago

OKYO

Okyo Pharma announces plans to accelerate development of urcosimod

OKYO Pharma (OKYO) announces plans to accelerate the clinical development of urcosimod to treat Neuropathic Corneal Pain, NCP,...

4M ago

OKYO

OKYO Pharma Achieves Key Stability Milestone for Urcosimod

The latest announcement is out from OKYO Pharma Limited Sponsored ADR ( ($OKYO) ). On March 31, 2025,...

5M ago

OKYO

OKYO FAQ

What was OKYO Pharma Limited Sponsored ADR’s price range in the past 12 months?

OKYO Pharma Limited Sponsored ADR lowest stock price was $0.90 and its highest was $3.35 in the past 12 months.

What is OKYO Pharma Limited Sponsored ADR’s market cap?

OKYO Pharma Limited Sponsored ADR’s market cap is $89.89M.

When is OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date?

OKYO Pharma Limited Sponsored ADR’s upcoming earnings report date is Aug 05, 2025 which is 25 days ago.

How were OKYO Pharma Limited Sponsored ADR’s earnings last quarter?

OKYO Pharma Limited Sponsored ADR released its earnings results on Nov 29, 2024. The company reported -$0.09 earnings per share for the quarter, the consensus estimate of -$0.09 by $0.

Is OKYO Pharma Limited Sponsored ADR overvalued?

According to Wall Street analysts OKYO Pharma Limited Sponsored ADR’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does OKYO Pharma Limited Sponsored ADR pay dividends?

OKYO Pharma Limited Sponsored ADR does not currently pay dividends.

What is OKYO Pharma Limited Sponsored ADR’s EPS estimate?

OKYO Pharma Limited Sponsored ADR’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does OKYO Pharma Limited Sponsored ADR have?

OKYO Pharma Limited Sponsored ADR has 37,610,676 shares outstanding.

What happened to OKYO Pharma Limited Sponsored ADR’s price movement after its last earnings report?

OKYO Pharma Limited Sponsored ADR reported an EPS of -$0.09 in its last earnings report, expectations of -$0.09. Following the earnings report the stock price went up 1.603%.

Which hedge fund is a major shareholder of OKYO Pharma Limited Sponsored ADR?

Currently, no hedge funds are holding shares in OKYO

OKYO Pharma Limited Sponsored ADR Stock Smart Score

Neutral

Company Description

OKYO Pharma Limited Sponsored ADR

OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

OKYO Pharma Limited Sponsored ADR (OKYO) Earnings & Revenues

Historic Earnings Reports

OKYO Stock 12 Month Forecast

Average Price Target

$10.00

▲(338.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","14":"$14","3.5":"$3.5","10.5":"$10.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$13.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.5,7,10.5,14],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Oct<br/>2024","9":"Mar<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,3.4092307692307693,4.208461538461538,5.007692307692308,5.806923076923077,6.6061538461538465,7.405384615384616,8.204615384615385,9.003846153846155,9.803076923076924,10.602307692307694,11.401538461538461,12.20076923076923,{"y":13,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,3.1784615384615384,3.7469230769230766,4.315384615384615,4.883846153846154,5.452307692307692,6.020769230769231,6.589230769230769,7.157692307692308,7.726153846153846,8.294615384615385,8.863076923076923,9.43153846153846,{"y":10,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.61,2.9476923076923076,3.2853846153846153,3.623076923076923,3.960769230769231,4.298461538461538,4.636153846153846,4.973846153846154,5.311538461538461,5.649230769230769,5.986923076923077,6.3246153846153845,6.662307692307692,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.66,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.94,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.49,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.46,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.24,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.04,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1.26,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.61,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >